Business
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study
About this update from Cervomed Inc.
[{"type":"image","alt":"CervoMed Inc.","displaySize":"","headline":null,"caption":"CervoMed Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/59afd81325b0c8128225f052847e0aa6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YRNF9gHnIhIY0CXM.LMRnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/59afd81325b0c8128225f052847e0aa6","width":300,"height":93}},"lazy":false},{"type":"text","content":"BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).","length":552,"tagName":"p"},{"type":"text","content":"Details of the AP/PD™ presentation are as follow:","length":49,"tagName":"p"},{"type":"text","content":"Abstract Title: Efficacy and safety results of the RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)Format: Oral PresentationPresenters: John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB Study and Stephen Gomperts, MD, PhD, Associate Professor of Neurology at Harvard Medical School and Director, Lewy Body Dementia Unit at the Massachusetts General Hospital.Session Name: Advances in PD, LBD, and MSA Drug Development Presentation Date and Time: Saturday, April 5th, 2025, 18.25-18.40 pm CET","length":559,"tagName":"p"},{"type":"text","content":"The abstract will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/ following the presentation.","length":133,"tagName":"p"},{"type":"text","content":"About CervoMedCervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat s...